| Developers: | Illumina |
| Last Release Date: | 2021/01/15 |
| Branches: | Pharmaceutics, medicine, health care |
Main article: DNA sequencing
2021: Registration in the Russian Federation
On January 15, 2021 the R-Pharm group announced registration for territories of the Russian Federation of set of MiSeq Dx v3 reagents for sequencing of nucleinic acids. This registration certificate, together with the MiSeq Dx sequenator registered earlier from Illumina company, announces emergence in the market of the ready IVD solution in the field of sequencing of the last generation (NGS) and will allow the Albiogen company entering into R-Pharm group to provide products for clinical genetic diagnostics of a number of dangerous diseases, including orphan diseases.
The desktop MiSeq Dx sequenator developed by Illumina company as which official representative in the territory of Russia the R-Pharm group acts is intended for a range of research tasks, first of all, targetny sequencing, sequencing of small genomes, profiling of an expression of genes and many other things. The universality of the device, high performance and convenience of the user (the built-in analyzer of data) give to MiSeq Dx exclusive advantages of application in clinical practice.
 | Emergence in the territory of our country of the complete diagnostic solution which allows timely and with a fine precision to reveal life-threatening diseases – the next big step on the way of increase in availability of advanced methods of protection of health to the Russian patients, – the CEO of Albiogen Andrey Frolov emphasized. |  |
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |